{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:09:09Z","timestamp":1792786149760,"version":"4.5.0"},"reference-count":108,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Start-up Fund for Talent Introduction of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine","award":["yjgjzcrc\u00e2\u20ac\u201d202402"],"award-info":[{"award-number":["yjgjzcrc\u00e2\u20ac\u201d202402"]}],"id":[{"id":"https:\/\/ror.org\/052q26725","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Clinical Medical Science and Technology Innovation Program of Jinan","award":["202430045"],"award-info":[{"award-number":["202430045"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This study was designed to assess the risk of programmed cell death-1 (PD-1) or programmed cell death ligand 1 (PD-L1) related rash in various situations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Guided by Preferred Reporting Items for Systematic Reviews and Meta-Analyses, data on rash in clinical trials related to PD-1 or PD-L1 were collected to comprehensively evaluate its incidence risk in various situations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Ninety-five clinical trials, divided into 12 groups according to treatment regimens, were enrolled for the final comprehensive assessments and analyses. Compared with chemotherapy or placebo alone, both PD-1 and PD-L1 inhibitors increased the risk of developing rashes for all grades (odds ratio [OR]\u2005=\u20051.61,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0003; OR\u2005=\u20052.94,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.00001). Whether used in combination with chemotherapy or other types of immunosuppressants, similar risk trends were observed (OR\u2005=\u20052.42,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.00001; OR\u2005=\u20052.11,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0007; OR\u2005=\u20054.49,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.00001; OR\u2005=\u20055.15,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0006; OR\u2005=\u20053.16,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Both PD-1 and PD-L1 increased the risk of rash occurrence, especially when used in combination with other immunosuppressive antitumor drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049720","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:02:19Z","timestamp":1783720939000},"page":"e49720","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The risk of rash for cancer patients treated with PD-1\/PD-L1 inhibitors: An updated systematic review and meta-analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Qunqun","family":"Jiang","sequence":"first","affiliation":[{"name":"Dermatological Department, The 970th Hospital of the Joint Logistics Support Force of the People\u2019s Liberation Army of China, Weihai, Shandong, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junru","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yantai Yuhuangding Hospital, Yantai, Shandong, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoqi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Dang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-1246","authenticated-orcid":false,"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"R2-20261001","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"R5-20261001","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma.","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/j.cllc.2018.01.004","article-title":"Atezolizumab in Japanese patients with previously treated advanced non-small-cell lung cancer: a subgroup analysis of the phase 3 OAK study.","volume":"19","author":"Hida","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden.","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial.","volume":"14","author":"Wu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"R11-20261001","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ijc.33399","article-title":"Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.","volume":"148","author":"Wu","year":"2021","journal-title":"Int J Cancer"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA).","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J Clin Oncol"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"},{"key":"R14-20261001","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41467-022-28408-3","article-title":"Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).","volume":"13","author":"Xu","year":"2022","journal-title":"Nat Commun"},{"key":"R18-20261001","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","article-title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.","volume":"34","author":"Chan","year":"2023","journal-title":"Ann Oncol"},{"key":"R19-20261001","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial.","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"R21-20261001","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC.","volume":"16","author":"Jassem","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R22-20261001","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1200\/JCO.20.00892","article-title":"Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100.","volume":"39","author":"Moehler","year":"2021","journal-title":"J Clin Oncol"},{"key":"R23-20261001","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"R24-20261001","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer.","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"R25-20261001","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"R26-20261001","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study.","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"R27-20261001","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial.","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12).","volume":"16","author":"Zhou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R29-20261001","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"R30-20261001","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study.","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"R31-20261001","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-lung 3 part 2 trial.","volume":"18","author":"Makharadze","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R32-20261001","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01).","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"R33-20261001","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"R34-20261001","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"R35-20261001","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study.","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"key":"R36-20261001","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial.","volume":"15","author":"Jotte","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R37-20261001","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"R38-20261001","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133).","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"R39-20261001","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer.","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"R40-20261001","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"R41-20261001","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer.","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"R42-20261001","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1038\/s41591-022-02126-1","article-title":"Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.","volume":"28","author":"R\u00f8ssevold","year":"2022","journal-title":"Nat Med"},{"key":"R43-20261001","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with pembrolizumab in early triple-negative breast cancer.","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"R44-20261001","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study.","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"R45-20261001","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"R46-20261001","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma.","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"R47-20261001","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial.","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"R48-20261001","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10388-022-00970-1","article-title":"First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648\/ONO-4538-50).","volume":"20","author":"Kato","year":"2023","journal-title":"Esophagus"},{"key":"R49-20261001","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"R50-20261001","doi-asserted-by":"crossref","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"key":"R51-20261001","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"key":"R52-20261001","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial.","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"R53-20261001","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"R54-20261001","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"R55-20261001","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"R56-20261001","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer.","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"R57-20261001","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309).","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"R58-20261001","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"key":"R59-20261001","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.21.02772","article-title":"Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: primary results of the randomized phase III IMpassion050 trial.","volume":"40","author":"Huober","year":"2022","journal-title":"J Clin Oncol"},{"key":"R60-20261001","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial.","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R61-20261001","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2022.12.017","article-title":"Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced nonsquamous NSCLC: extended follow-up of CameL phase 3 trial.","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R62-20261001","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial.","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"R63-20261001","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"R64-20261001","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"R65-20261001","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39).","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"key":"R66-20261001","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.","volume":"32","author":"Sugawara","year":"2021","journal-title":"Ann Oncol"},{"key":"R67-20261001","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"R68-20261001","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1111\/cas.15564","article-title":"Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).","volume":"113","author":"Kenmotsu","year":"2022","journal-title":"Cancer Sci"},{"key":"R69-20261001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","article-title":"Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"R70-20261001","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"R71-20261001","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma.","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"R72-20261001","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(22)01654-3","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.","volume":"400","author":"Livingstone","year":"2022","journal-title":"Lancet"},{"key":"R73-20261001","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.","volume":"23","author":"Long","year":"2022","journal-title":"Lancet Oncol"},{"key":"R74-20261001","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial.","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"R75-20261001","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451.","volume":"39","author":"Owonikoko","year":"2021","journal-title":"J Clin Oncol"},{"key":"R76-20261001","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma.","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"R77-20261001","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"R78-20261001","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"R79-20261001","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1200\/JCO.22.00620","article-title":"Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial.","volume":"41","author":"Qin","year":"2023","journal-title":"J Clin Oncol"},{"key":"R80-20261001","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma.","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"R81-20261001","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"R82-20261001","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"R83-20261001","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"R84-20261001","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"R85-20261001","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.22.00533","article-title":"Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915).","volume":"41","author":"Weber","year":"2023","journal-title":"J Clin Oncol"},{"key":"R86-20261001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"R87-20261001","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial.","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"R88-20261001","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"R89-20261001","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study.","volume":"41","author":"de Castro","year":"2023","journal-title":"J Clin Oncol"},{"key":"R90-20261001","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"R91-20261001","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"R92-20261001","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"R93-20261001","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study.","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"key":"R94-20261001","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet"},{"key":"R95-20261001","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"R96-20261001","doi-asserted-by":"crossref","first-page":"4976032","DOI":"10.1155\/2022\/4976032","article-title":"Risk of rash in PD-1 or PD-L1-related cancer clinical trials: a systematic review and meta-analysis.","volume":"2022","author":"Tian","year":"2022","journal-title":"J Oncol"},{"key":"R97-20261001","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.jtho.2019.05.020","article-title":"Immune-related adverse events (irAEs) predict for clinical efficacy: focusing on organ-specific irAEs and the critical role of steroids.","volume":"14","author":"Yang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R98-20261001","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jtho.2019.02.031","article-title":"Immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer: a predictive marker of efficacy?","volume":"14","author":"Remon","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R99-20261001","doi-asserted-by":"crossref","first-page":"e16038","DOI":"10.1200\/JCO.2019.37.15_suppl.e16038","article-title":"Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).","volume":"37","author":"Pier Vitale","year":"2019","journal-title":"J Clin Oncol"},{"key":"R100-20261001","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R101-20261001","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R102-20261001","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","article-title":"Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.","volume":"27","author":"Spain","year":"2016","journal-title":"Ann Oncol"},{"key":"R103-20261001","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R104-20261001","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R105-20261001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R106-20261001","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R107-20261001","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"key":"R108-20261001","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jama.2018.6971","article-title":"Odds ratios-current best practice and use.","volume":"320","author":"Norton","year":"2018","journal-title":"JAMA"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:01:28Z","timestamp":1790881288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":108,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049720","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"2024-09-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}